AVIR Atea Pharmaceuticals

Atea Pharmaceuticals to Host Third Quarter Financial Results Conference Call on November 11, 2021

Atea Pharmaceuticals to Host Third Quarter Financial Results Conference Call on November 11, 2021

BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Thursday, November 11, 2021 at 4:30 p.m. ET to report financial results for the third quarter ended September 30, 2021, and to provide a clinical and corporate update.

To access the live conference call, please dial (833) 301-1150 (domestic) or (914) 987-7391 (international) at least five minutes prior to the start time, and refer to conference ID 8846517. A live audio webcast of the call and accompanying slide presentation will be available in the Investors’ Events & Presentations section of the Company's website, . An archived webcast will be available on the Atea website approximately two hours after the event.

About Atea Pharmaceuticals

Atea Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing oral therapeutics to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging the Company’s deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea has built a proprietary nucleotide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases. Currently, Atea is focused on the development of orally-available, potent, and selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, dengue virus, hepatitis C virus (HCV) and respiratory syncytial virus (RSV). For more information, please visit .

Contacts

Jonae Barnes

SVP, Investor Relations and Corporate Communications

617-818-2985

Will O’Connor

Stern Investor Relations

212-362-1200



EN
04/11/2021

Underlying

AVIRAtea Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Atea Pharmaceuticals

 PRESS RELEASE
Free
AVIR Atea Pharmaceut...

Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44t...

Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference Phase 3 Topline Results for Potential Best-in-Class Regimen for Treatment of HCV on Track for 2026 Topline Results from North American Phase 3 C-BEYOND Trial Expected Mid-2026; Results from C-FORWARD Trial Outside North America Expected Year-End 2026 C-BEYOND and C-FORWARD Are the First Global Phase 3 Head-to-Head Trials of Direct-Acting Antivirals for Treatment of HCV Initiation of HEV Phase 1 Clinical Program for Product Candidate AT-587 Anticipated Mid-2026 BOSTON, Jan. 0...

January 8, 2026 1 EN
 PRESS RELEASE
Free
AVIR Atea Pharmaceut...

Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthc...

Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, together with other members of the Atea management team, will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026 at 7:30 a.m. PT ...

January 6, 2026 1 EN
 PRESS RELEASE
Free
AVIR Atea Pharmaceut...

Atea Pharmaceuticals Completes Patient Enrollment in North American Ph...

Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus Enrollment Completed in C-BEYOND Phase 3 Trial with More Than 880 HCV Treatment-Naïve Patients in US and Canada C-BEYOND Topline Results Expected Mid-2026 C-FORWARD Phase 3 Trial, Conducted Outside North America, Enrollment Completion Expected Mid-2026 with Topline Results Anticipated Year-End 2026 C-BEYOND AND C-FORWARD are the First Global Phase 3 Head-to-Head Trials of Direct-Acting Antivirals for Treatment of HCV BOSTON...

December 22, 2025 1 EN
 PRESS RELEASE
Free
AVIR Atea Pharmaceut...

Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare ...

Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, together with other members of the Atea management team, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Wednesday, December 3, 2025 ...

November 19, 2025 1 EN
 PRESS RELEASE
Free
AVIR Atea Pharmaceut...

Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and ...

Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update Patient Enrollment on Track in Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV), Topline Results from North America Trial Expected Mid-2026  New Data Show Bemnifosbuvir Has Unique Dual Mechanism Against HCV New Data Presented at The Liver Meeting®, the Annual Meeting of AASLD, Support Bemnifosbuvir/Ruzasvir as a Potential Best-in-Class Therapy for the Treatment of HCV Company Announces New Hepatitis E Virus (HEV) Development Program Company Holding Conference Call Today at 4:30 ...

November 12, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch